An open label, three-way crossover study to evaluate the absolute bioavailability of two formulations of Wafermine Trademark, a novel sublingual wafer formulation of ketamine, in healthy volunteers under fasted conditions.
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs Ketamine (Primary) ; Ketamine
- Indications Pain
- Focus Pharmacokinetics
- Sponsors iX Biopharma
- 18 May 2017 Status changed from not yet recruiting to completed.
- 28 Jan 2017 New trial record